Biotechnology
Excerpt from the Press Release: The FDA wanted a couple more clinical studies for Qualigen’s investigational COVID-19 antiviral before human testing, but the biotech is calling it quits instead. Shares of the company plunged nearly 20% to $1.34 as the markets opened Tuesday, underscoring the risk that small companies take on when trying to jump…
Read More
Excerpt from the Press Release: Subsidies, tax breaks and funding will keep momentum going in Canada’s promising biomanufacturing industry. Why weren’t we better prepared? The frantic search for gloves and masks, then ventilators and life-saving drugs, and then the scramble to ramp up testing, slow the deaths in long-term care and deploy vaccines — the…
Read More
Excerpt from the Article: While the first two Covid-19 vaccines relying on messenger RNA technology speed toward regulatory approval in the U.S., it’s worth remembering the vehicle that gets them where they need to go in the body. Lipid nanoparticles are the fatty molecular envelopes that help strands of mRNA — the genetic messenger for…
Read More
Excerpt from the Article: In children with spina bifida, the neural tube that forms the spinal cord and brain doesn’t close during early prenatal development. That leaves the nerves of the spinal cord exposed to potential damage from fetal movement and the surrounding amniotic fluid. While surgeons can repair spina bifida soon after birth, the…
Read More
Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Ufovax, LLC, (Ufovax), a vaccine biotechnology company based on the patented One-component Self-Assembling protein NanoParticle® (1c-SApNP®) vaccine design and manufacturing platform invented by Associate Professor Jiang Zhu, PhD, of Scripps Research (La Jolla, CA), announced the advancement toward Phase I clinical trials of its next-generation SARS-CoV-2 (aka “COVID-19”)…
Read More- « Previous
- 1
- …
- 31
- 32
- 33